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Objectives
Children with HIV associated tuberculosis often require
co-formulated lopinavir/ritonavir (LPV/RTV)-based anti-
retroviral treatment with rifampicin-based antitubercular
treatment (ATT). Rifampicin (RIF), a potent inducer of
drug-metabolizing systems, profoundly reduces the bioa-
vailability of LPV. The aims of this study were to
develop an integrated population pharmacokinetic (PK)
model describing LPV and RTV PK in children with
and without concomitant ATT using two different dos-
ing approaches and to estimate doses of LPV/RTV
achieving target exposures during ATT in young
children.
Methods
A population PK analysis was conducted in NONMEM.
During ATT 15 children were given LPV with extra
RTV (LPV/RTV ratio 1:1) and 20 children were given
twice the usual dose of LPV/RTV (ratio 4:1) 12 hourly;
39 children without tuberculosis and 11 children under-
going repeated sampling after ATT were treated with
standard 12 hourly doses of LPV/RTV (median LPV
dose 11.6 mg/kg). Goodness-of-fit plots and visual pre-
dictive checks were used to evaluate the models.
Results
In a one-compartment model with first-order absorption
to describe LPV PK, and a one-compartment model
with transit absorption for RTV, the dynamic influence
of RTV concentration on the clearance of LPV was
modelled as direct inhibition with an Emax model. Allo-
metric scaling for weight was used for clearance and
volume of both LPV and RTV. During ATT, the relative
oral bioavailability of LPV was reduced by 79% in chil-
dren receiving twice the usual dose of LPV/RTV. The
clearance of RTV was 18 L/h with, and 13 L/h without,
ATT. The baseline clearance of LPV, when RTV was
undetected, estimated 4.34 L/h. With increasing concen-
trations of RTV, clearance of LPV decreased in a sig-
moid relationship (EC50 0.051 mg/L). Volume of
distribution for LPV and RTV were 11.7 and 102 L,
respectively. Simulations predicted that children weigh-
ing 4-6, 6-8, 8-12 and 12-18 kg need respective doses of
65, 50, 37 and 30 mg/kg LPV/RTV (4:1) 8 hourly in
order to maintain LPV concentrations > 1 mg/L in at
least 95% of children.
Conclusions
The model describes the drug-drug interaction between
LPV, RTV and RIF. Using 8 hourly doses, approximately
2.5 to 5.5 times the standard doses are required to
maintain therapeutic LPV concentrations in young chil-
dren during ATT.
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